Clinical Trials Logo

Filter by:
NCT ID: NCT06097637 Recruiting - Haemorrhage Clinical Trials

Underwater Endoscopic Mucosal Resection Versus Metal Clips With Hot Snare Polypectomy for Resection of Big Pedunculated Colorectal Polyps:a Randomized Controlled Trial

Start date: October 19, 2023
Phase: N/A
Study type: Interventional

Endoscopic resection of pedicled polyps mainly focuses on how to prevent bleeding, and also needs to pay attention to the convenience of resection and the integrity of resection, which means that different endoscopic resection strategies should be adopted for pedicled polyps with different pedicle sizes. The head larger than 20mm or pedicle larger than 5mm are defined as large pedicle polyps, which are at greater risk of bleeding. Current guidelines recommend hot removal by snare following preoperative saline injection, ligation of the pedicle with a nylon ring or metal clip, depending on the size of the polyp head and pedicle. However, the use of snares and metal clamps does not appear to reduce delayed postoperative bleeding, and the technical requirements of nylon ligation are relatively high. Recent studies have found that Underwater endoscopic mucosal resection (UEMR) is also safe and effective for the treatment of large and medium colorectal stemless polyps. Therefore, it is still necessary to further explore new safe and effective endoscopic resection strategies and techniques.

NCT ID: NCT06097065 Recruiting - Diabetes Mellitus Clinical Trials

Research on Potential Biomarkers of Prediabetes and Diabetes Based on MALDI-TOF MS Platform.

Start date: May 20, 2022
Phase:
Study type: Observational

Through the MALDI-TOF MS platform, explore the proteomics and peptidomics differences of fasting serum/plasma and urine between non pregnant people with normal glucose tolerance test and prediabetes /diabetes patients, pregnant people with normal glucose tolerance test and pregnant diabetes patients respectively; To explore the role of its proteomics and peptidomics differences in the diagnosis of prediabetes and diabetes, and to establish a new method of differential diagnosis by using the omics data and key characteristic peaks to find potential new diagnostic markers.

NCT ID: NCT06096922 Recruiting - Frailty Clinical Trials

AI-based Frailty Assessment Tool for Patients Undergoing Cardiac Surgery

Start date: November 1, 2023
Phase:
Study type: Observational

The main purpose of this study is to establish a frailty automatic evaluation index "AI frailty index" based on artificial intelligence multi-modal non-contact monitoring information analysis. At the same time, the study will explore the correlation between ' AI weakness index ' and perioperative and long-term prognosis and quality of life.

NCT ID: NCT06096805 Recruiting - Clinical trials for Fetal Growth Retardation

Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR)

Start date: August 10, 2023
Phase:
Study type: Observational

This study intends to prospectively enroll high-risk pregnant women to establish a multicenter cohort. By combining maternal basic characteristics, medical history, early pregnancy ultrasound, and biological markers, we aim to construct a joint predictive model for MVM-FGR.

NCT ID: NCT06096766 Recruiting - Aging Clinical Trials

the Correlation Between Ovarian Function and Serum Biomarkers

Start date: October 25, 2023
Phase:
Study type: Observational

The goal of this observational study is to find differences in serum biomarkers between ovarian function and normal individuals.

NCT ID: NCT06096285 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Heterogeneity and Development of Early COPD

Start date: February 1, 2023
Phase:
Study type: Observational

This study aims to investigate the clinical characteristics and heterogeneities of early chronic obstructive pulmonary disease (COPD), to determine the disease development of early COPD, and to establish a multidimensional model for predicting the outcomes of early COPD.

NCT ID: NCT06095934 Recruiting - NSCLC Clinical Trials

Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

To evaluate the efficacy (ORR) and safety of anti PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy in the treatment of advanced NSCLC progressed after EGFR-TKI treatment and to provide new treatment methods for EGFR-TKI resistant patients.

NCT ID: NCT06095778 Recruiting - Clinical trials for Major Depressive Disorder

rTMS Therapy for Treatment-Resistant Depression With Different Targets Guided by pBFS

Start date: November 6, 2023
Phase: N/A
Study type: Interventional

To explore the effectiveness and safety of rTMS intervention with different targets in the left prefrontal cortex defined using the pBFS method, in adult patients with moderate and severe depressive disorder. Second, investigate the neural circuit that responds to the rTMS intervention using individualized brain image analysis, which may help to establish an effective target for the neuromodulation of patients with major depressive disorder.

NCT ID: NCT06095596 Recruiting - Crohn Disease Clinical Trials

Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

It's of great importance to effectively induce and maintain disease remission in patients with moderate to severe ulcerative colitis (UC). Vedolizumab (VDZ) is known for its high safety profile and confirmed therapeutic efficacy in UC treatment. However, according to the experience in clinical practice, the effect onset speed of vedolizumab is relatively slow. Upadacitinib (UPA), however, works quickly, which complements the defect of slow onset of VDZ induction. However, the safety of UPA used in situations such as infection and tumors is inferior to that of VDZ, and long-term use requires testing for the risk of adverse events such as deep vein thrombosis. Therefore, if the advantages of long-term maintenance therapy safety of VDZ and rapid induced remission of UPA are fully utilized, the combination of VDZ and UPA induction for 8 weeks, followed by the use of single drug VDZ in maintenance therapy, can maximize the clinical benefits of UC patients. Due to the lack of high-level clinical research data at home and abroad, we plan to conduct a multicenter prospective randomized controlled clinical study to provide the evidence-based basis for the efficacy analysis of the sequential treatment of moderate to severe UC patients with VDZ and UPA.

NCT ID: NCT06095583 Recruiting - Clinical trials for Limited-stage Small Cell Lung Cancer (LS-SCLC)

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Start date: November 15, 2023
Phase: Phase 3
Study type: Interventional

The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death protein-1 (PD-1). Neither drug is approved for treatment of This combination regimen is investigational in limited stage-small cell lung cancer in any country.